Tuesday, 16 Jul 2019

You are here

Improving Cardiovascular Trends in Rheumatoid Arthritis

 Myasoedova and colleagues from the Mayo Clinic have reported their new data that demonstrates improving cardiovascular (CV) mortality rates in current RA patients treated with modern drugs.

They studied 813 RA patients (mean age 55.9 years; 68% female). In patients with incident RA during the 2000–2007 period, the 10-year CV mortality was 2.8% (95% CI: 0.4%, 5.2%) and coronary heart disease (CHD) mortality was 1.2% (1.0, 1.4%). These numbers demonstrate significant improvement when compared to patients diagnosed in 1990–1999. Lower rates of CV outcomes included the overall CV death rate (HR=0.43; 95% CI: 0.19, 0.94; p=0.035); and CHD death (HR 0.21; 95% CI: 0.05, 0.95).

Importantly, the lowering of RA death rates now show them to not be different than the non-RA cohort (general population). 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

CRP Utility in COPD Exacerbations

NEJM reports on the utility of C-reactive protein (CRP) testing in chronic obstructive pulmonary disease (COPD) patients, showing that CRP guided prescribing of antibiotics for exacerbations of COPD in primary care clinics resulted in a lower percentage of patients who reported antibiotic use.

EULAR 2019 - Day 1 Report

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Here are a few of the highlights from day 1 EULAR in Madrid, including another IL-23 inhibitor, BTK inhibition, abatacept in Sjogren's syndrome, don't repeat the ANA, and drug free remission in systemic JIA.

Borrelia burgdorferi Peptidoglycan Shedding Drives Lyme Arthritis

Research published in PNAS has shown that long after active Lyme infection in the joint, a peptidoglycan (PG) of the the spirochete Borrelia burgdorferi can be found in the joints of those with late-stage Lyme disease.

 

EULAR 2019 - Day 1 Report

Here are a few of the highlights from day 1 EULAR in Madrid. 

Low Remission/LDA Rates with TNF inhibitors in Rheumatoid Arthritis

 

Analysis of Rheumatoid Arthritis patients enrolled and treated as part of the British Society for Rheumatology Biologics Registry shows that sustained remission or low disease activity state (LDA) on TNF inhibitor treatment is uncommon and that combing methotrexate with an anti-TNF increases the odds of sustained remission/LDA.